Henry GeorgeHead, Viral Vectors and Viral Gene Therapy Bioprocessing R&D at MilliporeSigma, USA
Henry George brings expertise in research and product development through professional experience in both small biotechnology and large pharmaceutical industries. Henry received his B.A. degree in biology from Southern Illinois University at Edwardsville in 1976, and performed graduate studies in genetics at Florida State University and biochemistry at St. Louis University. Since 1981, Henry has worked in both the biotechnology and pharmaceutical sectors, developing recombinant protein expression systems in bacterial, insect and mammalian hosts. In early 2001, he joined Sigma-Aldrich and worked to lead teams and develop products including the FLAG(R) protein expression system, Mission™ lentiviral shRNA libraries, and improved and novel CHO cell lines (CHOZN) used for the manufacturing of biopharmaceuticals.
In 2016, he joined MilliporeSigma’s Process Solutions R&D group (Gene Editing and Novel Modalities) to head up a new team (Viral Vectors and Viral Gene Therapy Bioprocessing R&D) focusing on improving the systems and bioprocesses for viral vector manufacturing for clinical and commercial gene therapy applications.
Henry’s research experience covers a multitude of scientific disciplines including molecular biology, gene expression, cell biology, virology, and protein chemistry. His work has resulted in publications in journals such as Science, Proceedings of the National Academy of Science, the Journal of Biological Chemistry, Biochemistry, and DNA.